With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback